Literature DB >> 19775662

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.

Chris H Takimoto1.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19775662     DOI: 10.1016/S0959-8049(09)70080-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  6 in total

Review 1.  Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Authors:  Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti
Journal:  Target Oncol       Date:  2010-04-02       Impact factor: 4.493

Review 2.  Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.

Authors:  Abhijit Pal; Rajiv Shinde; Manuel Selvi Miralles; Paul Workman; Johann de Bono
Journal:  Nat Rev Clin Oncol       Date:  2021-03-24       Impact factor: 66.675

Review 3.  The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.

Authors:  Qingyu Zhou; James M Gallo
Journal:  AAPS J       Date:  2011-01-19       Impact factor: 4.009

4.  Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.

Authors:  Shinji Yamazaki
Journal:  AAPS J       Date:  2012-12-19       Impact factor: 4.009

Review 5.  Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Authors:  Joo Ern Ang; Stan Kaye; Udai Banerji
Journal:  Curr Drug Targets       Date:  2012-11       Impact factor: 3.465

6.  Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.

Authors:  Yingfang Fan; Najia Mansoor; Tasneem Ahmad; Rafeeq Alam Khan; Martin Czejka; Syed Sharib; Dong-Hua Yang; Mansoor Ahmed
Journal:  Oncotarget       Date:  2017-07-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.